$45.99 / month – $389.99
Cardiogen peptide (AEDR) is a Khavinson tetrapeptide bioregulator targeting cardiac muscle tissue. This research-grade compound modulates gene expression in cardiomyocytes and cardiac fibroblasts for preclinical cardiovascular aging and cardioprotection research. 20mg lyophilized powder, =98% purity, COA included.
Cardiogen peptide is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Arg (AEDR), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Cardiogen targets cardiac muscle tissue, functioning as a heart bioregulator that tunes gene expression in cardiomyocytes, cardiac fibroblasts, and supporting heart tissue. It belongs to the Khavinson bioregulator peptides class — short control peptides that show tissue-specific gene expression tuning at natural levels — and has been studied in lab models of age-related heart decline, myocardial remodeling, and cardiac aging.
Heart disease remains the leading cause of age-related morbidity and mortality worldwide, yet the underlying epigenetic mechanisms of cardiac aging are only beginning to be understood. Cardiogen addresses this key research gap by operating at the gene-expression level in cardiac tissue, offering a fundamentally different research approach compared to receptor agonists or hemodynamic modulators. Among the Khavinson bioregulator peptides, cardiogen is uniquely tissue-specific to the heart, making it the main cardiac bioregulator peptide for heart aging research. PrymaLab Cardiogen 20mg is manufactured to high purity standards and supplied exclusively for qualified lab research.
| Specification | Detail |
|---|---|
| Compound | Cardiogen (tetrapeptide bioregulator) |
| Sequence | Ala-Glu-Asp-Arg (AEDR) |
| Quantity | 20mg |
| Target Tissue | Cardiac muscle (cardiomyocytes, cardiac fibroblasts, conduction system) |
| Class | Khavinson bioregulator peptide (short control peptide) |
| Purity | ≥98% (HPLC-verified per batch) |
| Testing | HPLC, mass spectrometry, identity check |
| Form | Freeze-dried powder |
| Storage | Store at −20°C desiccated; protect from light |
| Intended Use | Lab research only — not for human or veterinary treatment use |
Cardiogen operates through the peptide-DNA interaction mechanism characterized by Professor Khavinson’s research group, wherein short control peptides selectively bind specific DNA sequences within gene promoter regions and alter chromatin conformation. In cardiac tissue, cardiogen tunes the expression of genes governing cardiomyocyte function, extracellular matrix homeostasis, energy-cell bioenergetics, and intercellular signaling. This epigenetic mechanism operates at physiologically relevant levels, distinguishing bioregulator peptides from pharmacological agents that need supraphysiological doses.
The tissue specificity of cardiogen peptide derives from the selective affinity of the AEDR sequence for control DNA motifs enriched in cardiac gene promoters. Lab studies have showed that cardiogen preferentially tunes gene expression in cardiomyocytes and cardiac fibroblasts while showing minimal transcriptional activity in non-cardiac cell types. This targeted activity profile makes cardiogen a valuable research tool for isolating cardiac-specific aging mechanisms from systemic heart changes.
Age-related cardiac decline involves progressive cardiomyocyte loss, compensatory hypertrophy, fibrotic remodeling, and diminished contractile reserve. Cardiogen research targets these processes at their transcriptional origin. Lab models show tuning of collagen deposition genes, anti-apoptotic signaling in cardiomyocytes, energy-cell biogenesis factors, and calcium handling proteins — all key components of the cardiac aging cascade that find the trajectory from healthy to pathological cardiac remodeling.
Published studies on cardiogen peptide benefits report multiple tissue-specific effects relevant to cardiac aging and heart research uses. All findings described below are from lab animal and cell culture models.
Cardiac fibrosis is one of the most major contributors to age-related heart failure, reducing myocardial compliance and impairing diastolic function. Cardiogen has showed dose-dependent suppression of fibrotic gene expression in lab cardiac models, including reduced collagen type I and type III deposition, decreased transforming growth factor beta (TGF-β) signaling, and restored matrix metalloproteinase balance. These anti-fibrotic effects position cardiogen as a unique research compound for studying the reversibility of age-related cardiac stiffening.
The adult heart has extremely limited regrowth capacity, making cardiomyocyte preservation key to cardiac longevity. Cardiogen research has shown upregulation of anti-apoptotic gene expression (including Bcl-2 family members) and enhanced cellular stress resistance in aged cardiomyocyte cultures. These findings suggest that cardiogen may help keep functional cardiomyocyte populations during aging by shifting the balance from pro-apoptotic to pro-survival transcriptional programs.
Cardiac muscle is the most mitochondria-dense tissue in the body, and age-related energy-cell dysfunction directly impairs contractile function. Among the reported cardiogen benefits, restoration of energy-cell biogenesis markers (PGC-1α, TFAM) and improved oxidant phosphorylation efficiency in aged cardiac tissue have specific significance for grasp the bioenergetic basis of cardiac aging.
Lab cardiogen studies report improved contractile parameters in aged cardiac preparations, correlated with enhanced expression of calcium handling proteins including SERCA2a and ryanodine receptor control subunits. These cell-level findings provide mechanistic insight into how gene expression tuning at the epigenetic level can translate into measurable functional gains in cardiac tissue.
Longitudinal animal studies by the Khavinson group have reported that cardiogen use is linked with kept cardiac function, reduced age-related structural remodeling, and preserved electrocardiographic parameters in aged cohorts compared to controls. These heart anti-aging findings form the foundation of ongoing bioregulatory gerontology research into cardiac lifespan extension.
Published research provides context for cardiogen peptide dosage parameters across different experimental paradigms. The following represents reported dosage ranges from lab literature and is intended solely to inform research protocol design.
| Research Use | Reported Dosage Range | Protocol Context |
|---|---|---|
| Cell Culture (Cardiomyocytes) | 10–100 nM | Gene expression tuning studies in isolated cardiomyocytes |
| Aging Cardiac Models | 1–10 µg/kg | Chronic use in aged rodent heart studies |
| Acute Cardiac Stress Models | 5–50 µg/kg | Pre- and post-stress cardioprotection paradigms |
| Combined Bioregulator Protocols | 1–10 µg/kg each | Multi-peptide regimens (e.g., cardiogen + vesilute) |
Important: These are reported research dosages from published lab literature. Best dosing depends on experimental design, animal model, route of use, and research objectives. This product is not intended for treatment use.
Researchers studying heart aging often compare cardiogen and vesilute because both target the heart system but through distinct tissue-specific mechanisms. Grasp their paired roles is essential for designing full heart bioregulator research protocols.
| Feature | Cardiogen | Vesilute |
|---|---|---|
| Classification | Heart bioregulator (cardiac tissue) | Vascular bioregulator (endothelial tissue) |
| Sequence | Ala-Glu-Asp-Arg (AEDR) | Lys-Glu-Asp (KED) |
| Main Target | Cardiomyocytes, cardiac fibroblasts | Vascular endothelium, smooth muscle |
| Heart Mechanism | Direct myocardial: gene expression in heart muscle cells | Vascular: gene expression in blood vessel walls |
| Anti-Aging Focus | Cardiac remodeling, fibrosis, cardiomyocyte loss | Endothelial dysfunction, vascular stiffening, cerebrovascular aging |
| Key Research Use | Myocardial aging, contractile decline, cardiac fibrosis | Vascular aging, blood-brain barrier, brain safety via cerebral vessels |
| Combined Use | Paired: heart muscle + blood vessels = whole heart system | Paired: blood vessels + heart muscle = whole heart system |
The cardiogen-vesilute mix represents the most full heart bioregulator research approach in the Khavinson system, with cardiogen addressing the muscular pump (myocardium) and vesilute addressing the conduit system (vasculature). Researchers studying systemic heart aging may benefit from protocols incorporating both peptides to capture the full spectrum of age-related heart tissue changes.
PrymaLab supplies Cardiogen 20mg as a high-purity research-grade heart bioregulator peptide verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each batch ships with a unique lot number and Certificate of Test. Independent third-party testing ensures unbiased quality check and full traceability for GLP-compliant heart research.
Cardiogen is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Arg, AEDR) developed by Professor Khavinson targeting cardiac muscle tissue. It tunes gene expression in cardiomyocytes, cardiac fibroblasts, and supporting heart tissue. Research uses include cardiac aging, myocardial remodeling, fibrosis, and heart anti-aging in lab models.
Published lab research reports cardiogen peptide benefits including anti-fibrotic effects in cardiac tissue (reduced collagen deposition, decreased TGF-β signaling), enhanced cardiomyocyte survival through anti-apoptotic gene upregulation, improved energy-cell bioenergetics (PGC-1α, TFAM restoration), enhanced calcium handling and contractile function, and kept cardiac structure in longitudinal aging models. All reported benefits are from lab research.
Cardiogen operates through epigenetic gene expression tuning in cardiac tissue rather than receptor agonism, enzyme blocking, or hemodynamic tuning. This means it targets the transcriptional programs governing heart function rather than acutely modifying cardiac physiology. Among Khavinson bioregulator peptides, cardiogen provides direct myocardial effects paired to vesilute’s vascular endothelial bioregulation.
Published cardiogen dosage ranges include 10–100 nM for cell culture studies and 1–10 µg/kg for in vivo aging models. Dosing depends on experimental design, model system, and research objectives. This product is for lab research only and is not intended for treatment dosing.
Store freeze-dried cardiogen at −20°C, desiccated and protected from light, for 24+ months shelf life. After mixing, store at 2–8°C and use within 2–4 weeks. Aliquot to avoid freeze-thaw cycles.
For Research Use Only. PrymaLab Cardiogen 20mg is intended exclusively for qualified lab research use. This product is not intended for human consumption, treatment use, veterinary treatment, or any use outside controlled research environments. Cardiogen has not been approved by the FDA or any equivalent control authority for treatment use. All research uses described are from published lab and gerontological literature. Researchers are responsible for control compliance.
| Weight | N/A |
|---|---|
| Dimensions | N/A |
Only logged in customers who have purchased this product may leave a review.
support@prymalab.net info@prymalab.net
30 Day return window. Satisfaction guaranteed or your money back.
All orders over %150 in value will receive free shipping.
Reviews
There are no reviews yet.